{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:15:37Z","timestamp":1782461737556,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.urology.2017.04.045","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T15:00:24Z","timestamp":1493996424000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie Disease"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-3936","authenticated-orcid":false,"given":"Matthew J.","family":"Ziegelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyd R.","family":"Viers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua B.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon W.","family":"Trost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2017.04.045_bib0010","first-page":"4S","article-title":"Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials","volume":"10","author":"Keefe","year":"2013","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.urology.2017.04.045_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/mpr.340","article-title":"How to assess the clinical impact of treatments on patients, rather than the statistical impact of treatments on measures","volume":"20","author":"Kraemer","year":"2011","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.urology.2017.04.045_bib0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","article-title":"Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire","volume":"190","author":"Hellstrom","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.04.045_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie's disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.04.045_bib0030","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","article-title":"Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls","volume":"5","author":"Rosen","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2017.04.045_bib0035","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1743-6109.2010.02102.x","article-title":"Five-year follow-up of Peyronie's graft surgery: outcomes and patient satisfaction","volume":"8","author":"Chung","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2017.04.045_bib0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11934-014-0415-4","article-title":"Update on medical management of Peyronie's disease","volume":"15","author":"Tan","year":"2014","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2017.04.045_bib0045","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bju.12565","article-title":"Outcomes of surgical treatment of Peyronie's disease","volume":"113","author":"Carson","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.04.045_bib0050","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bju.12968","article-title":"International multicentre psychometric evaluation of patient-reported outcome data for the treatment of Peyronie's disease","volume":"115","author":"Kueronya","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.04.045_bib0055","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.04.045_bib0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2017.04.045_bib0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.04.045_bib0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urology.2017.04.045_bib0075","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.04.045_bib0080","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.04.045_bib0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urology.2017.04.045_bib0090","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1111\/jsm.12312","article-title":"Baseline characteristics from an ongoing phase 3 study of collagenase Clostridium histolyticum in patients with Peyronie's disease","volume":"10","author":"Gelbard","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2017.04.045_bib0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.urology.2015.04.047","article-title":"Self-report and clinical response to Peyronie's disease treatment: Peyronie's disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies","volume":"86","author":"Hellstrom","year":"2015","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429517304697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429517304697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T23:51:11Z","timestamp":1535845871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429517304697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":18,"alternative-id":["S0090429517304697"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2017.04.045","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie Disease","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2017.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}